Helocyte
engages in the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious diseases... Read moreHelocyte
engages in the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious diseases... Read more
News
Oct 16, 2023
GlobalNewswire
Press Release: Helocyte : Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
Jun 15, 2023
BioSpace
Helocyte: Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
Feb 16, 2023
GlobalNewswire
Press Release: Helocyte : Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Feb 15, 2023
GlobalNewswire
Press Release: Helocyte : Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex
Aug 11, 2022
BioSpace
Helocyte: Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex
Dec 16, 2021
GlobalNewswire
Press Release: Helocyte : Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV
Dec 16, 2021
firstword pharma
Helocyte: Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV
Oct 29, 2016
4-traders
Helocyte: Fortress Biotech : Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood